hat
Monomethyl auristatin E oswa MMAE se 100-1000 fwa pi pisan pase doxorubicin (Adriamycin / Rubex) epi yo pa kapab itilize kòm yon dwòg tèt li. Sepandan, kòm yon pati nan yon konjigeur antikò-dwòg oswa ADC, Monomethyl auristatin E (MMAE, vedotin) se lye nan yon monoklon antikò (mab) ki rekonèt yon ekspresyon makè espesifik nan selil kansè epi li dirije MMAE nan yon selil kansè espesifik.
eng
Monomethyl auristatin E or MMAE is 100-1000 times more potent than doxorubicin (Adriamycin/Rubex) and cannot be used as a drug itself. However, as part of an antibody-drug conjugate or ADC, Monomethyl auristatin E (MMAE, vedotin) is linked to a monoclonal antibody (mAb) that recognizes a specific marker expression in cancer cells and directs MMAE to a specific, targeted cancer cell.